title: Simultaneous high-dose external irradiation and daily cisplatin in unresectable, non-metastatic adenocarcinoma of the pancreas: a phase I-II study.
abstract: OBJECTIVE
  Clinical trials have demonstrated that high dose radiation therapy and daily cisplatin (CDDP) could increase local control and survival in carcinoma from various sites. The present phase I-II study has combined high dose radiation therapy and daily CDDP at escalating dosages.
  
  
  METHODS
  From August 1994 to December 1995, 23 patients with non-resectable carcinoma of the pancreas were enrolled in a phase I-II multicentric, pilot study to test the toxicity and the effectiveness of high dose radiotherapy and daily cisplatin (CDDP) at escalating dosages. A dose of 6 mg/sqm/day of CDDP was selected for the phase II step since no grade IV toxicity occurred in any patient in the phase I step.
  
  
  RESULTS
  Toxicity was considered fairly acceptable. At the time of analysis, the 23 patients who entered the study had clear evidence of evolutive disease either locally or distantly in the liver. It is suggested that high dose radiotherapy (60 Gy continuously) and daily CDDP have little effect on local control of the tumor and survival, and only a moderate effect on pain.
  
  
  CONCLUSIONS
  In unresectable, apparently non-metastatic cancers of the pancreas, there is an urgent need for new agents or new combinations of agents to be tested.
authors.affiliation: Institut Jean-Godinot, Reims, France.
authors.forename: T D
authors.initials: TD
authors.lastname: Nguyen
authors.forename: S
authors.initials: S
authors.lastname: Theobald
authors.forename: P
authors.initials: P
authors.lastname: Rougier
authors.forename: M
authors.initials: M
authors.lastname: Ducreux
authors.forename: A
authors.initials: A
authors.lastname: Lusinchi
authors.forename: E
authors.initials: E
authors.lastname: Bardet
authors.forename: J C
authors.initials: JC
authors.lastname: Eymard
authors.forename: T
authors.initials: T
authors.lastname: Conroy
authors.forename: E
authors.initials: E
authors.lastname: Francois
authors.forename: J F
authors.initials: JF
authors.lastname: Seitz
authors.forename: R
authors.initials: R
authors.lastname: Bugat
authors.forename: M
authors.initials: M
authors.lastname: Ychou
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin